Qiming Venture Partners Weekly | Portfolio Companies Funding and Updates Vol. 29, 2025
Staying with you through the milestone moments of Qiming Venture Partners' portfolio companies.
Editor's Note: The "Qiming Weekly" column is published regularly every week, rounding up funding news and development updates from Qiming Venture Partners' portfolio companies.
In the wave of technology and innovation, every step entrepreneurs take deserves to be recorded. Qiming Venture Partners will continue to accelerate and empower entrepreneurs, and we invite you to join us in marking the milestone moments of our portfolio companies.
Corporate ESG
01/
Yuanbao Inc. Donates Medical Supplies Worth RMB 100,000 to Ulanqab, Inner Mongolia
Recently, medical supplies worth RMB 100,000 donated by Qiming Venture Partners portfolio company Yuanbao Inc. (NASDAQ: YB) — five defibrillator units — arrived safely in Zhuozi County, Ulanqab City, Inner Mongolia Autonomous Region.
The three medical defibrillator monitors and two automated external defibrillators (AEDs) donated by Yuanbao address critical shortages in Zhuozi County. AEDs, which can be operated by non-medical personnel, are life-saving devices for cardiac arrest patients. The equipment has been distributed by the county Red Cross to relevant departments at the county people's hospital and to township police stations under the county public security bureau.
02/
MedSci Health Receives Wind ESG AA Rating
Recently, global financial data provider Wind unveiled its 2025 ESG ratings. Qiming Venture Partners portfolio company MedSci Health (SEHK: 2415) earned a Wind ESG AA rating for its outstanding performance in environmental, social, and governance practices.
MedSci Health has achieved a leap in its ratings journey. Rising from BBB in 2023–2024 to AA in 2025, this marked improvement reflects the company's sustained commitment and determination to ESG development. In peer comparisons, MedSci Health leads with a comprehensive score of 8.63, setting an exemplary case for ESG management in the industry.
Funding News
Minghui Pharma Raises $131 Million in Pre-IPO Round Qiming Venture Partners Co-Leads
Recently, Minghui Pharma, a late-stage clinical biopharmaceutical company focused on oncology and autoimmune diseases, announced the completion of a $131 million Pre-IPO financing round co-led by Qiming Venture Partners. Proceeds will advance Minghui Pharma's clinical programs, with a focus on its PD-1/VEGF bispecific antibody and combination strategies with antibody-drug conjugates (ADCs), as well as support the commercial launch in China of its topical JAK inhibitor.
Dr. Kan Chen, Partner at Qiming Venture Partners and Co-Head of Healthcare Innovation, said: "Minghui Pharma has built a highly competitive pipeline of innovative drugs addressing unmet clinical needs. We are pleased to support the company in accelerating the delivery of transformative therapies to patients worldwide."
Major Partnerships
01/
Hesai Technology Partners with Vbot to Advance Commercialization of World's First Smart Companion Robot
Recently, Qiming Venture Partners portfolio company Hesai Technology (NASDAQ: HSAI) and Vbot, China's first consumer-grade embodied AI company, formally announced a deep strategic partnership.
This collaboration aims to drive breakthrough progress in robotic perception systems. By deeply integrating lidar with AI, the two companies are enabling robots to not only perceive the world with precision but also interact with flexibility — pressing the "accelerator" on the commercialization of embodied AI and creating the industry's first smart companion robot.
As AI and robotics technology converge, lidar is expanding from autonomous driving into broader robotics applications. The partnership between Hesai Technology and Vbot not only marks further refinement of the "perception-decision-execution" loop in robotics, but also signals that intelligent robots will unlock greater value in everyday human environments.
02/
East China University of Science and Technology Professor Gu Zhen's Team and Prismlab Launch Technical Solution Combining Precision Signal Capture with Convenience
Professor Gu Zhen's team at East China University of Science and Technology has partnered with Qiming Venture Partners portfolio company Prismlab to combine their Tri-PLA-RCA technology with micro-nano 3D-printed microfluidic chips, meeting clinical demand for a technical solution that can "precisely capture subtle signals while maintaining convenience."
The breakthrough lies in an ingenious "triple recognition" design: like using three keys to open a lock simultaneously, the signal is only activated when the target protein, sialylation site, and cis-diol site on the glycan chain are all recognized — fundamentally preventing false positives. Meanwhile, Prismlab's micro-nano 3D-printed ExoTRAP chip functions like a "miniature laboratory," compressing the entire exosome capture, washing, and detection workflow into a compact format. Processing time is reduced from 24 hours to 3 hours, with detection sensitivity reaching 2.81 × 10³ particles/mL — equivalent to precisely identifying a few specific nanoparticles in a liter of water. This "precision plus efficiency" combination fills the gap between conventional technology and clinical needs.
R&D Progress
01/
Gan & Lee Pharmaceuticals' GZR102 Injection Completes First Patient Dosing in China Phase 2 Clinical Study
Qiming Venture Partners portfolio company Gan & Lee Pharmaceuticals (603087.SH) recently announced that its self-developed basal insulin/glucagon-like peptide-1 receptor agonist (GLP-1RA) fixed-ratio combination weekly formulation, GZR102 Injection, has completed first-patient dosing in a Phase 2 clinical study in Chinese adults with type 2 diabetes (T2DM).
Basal insulin/GLP-1RA combination formulations are expected to simplify T2DM treatment regimens, delivering potent glucose-lowering effects while reducing adverse effects associated with basal insulin therapy such as weight gain and hypoglycemia — achieving "enhanced efficacy with fewer side effects" and improving patient adherence. Compared with traditional daily formulations, long-acting weekly formulations significantly reduce dosing frequency (by over 80% annually), potentially improving the treatment experience and long-term adherence. Currently, no basal insulin/GLP-1RA fixed-ratio combination weekly formulation has been approved globally. GZR102 Injection's rapid advancement into Phase 2 clinical trials positions it as a leading candidate in China for combination diabetes therapy, further broadening Gan & Lee's product pipeline in diabetes treatment.
02/
Huashan Hospital Officially Launches Phase 1/2 Registration Clinical Study of Shize Biotech's XS411 Injection for Early-Onset Parkinson's Disease
Recently, the launch meeting for "China's first randomized, double-blind, controlled clinical-grade iPSC-derived dopaminergic neural progenitor cell therapy (XS411 Injection) for early-onset Parkinson's disease registration clinical Phase 1/2 study" was officially held at Huashan Hospital, led by China's National Neurological Disease Medical Center at Fudan University-affiliated Huashan Hospital and co-organized with the Second Affiliated Hospital of Soochow University. This gold-standard clinical trial employs an allogeneic universal "off-the-shelf" iPSC-derived dopaminergic neural progenitor cell therapy product (XS411 Injection) independently developed by Qiming Venture Partners portfolio company Shize Biotech.
Dr. Xiang Li, founder of Shize Biotech, stated: "After more than four years of dedicated investment and intensive R&D, Shize Biotech's allogeneic universal 'off-the-shelf' iPSC-derived dopaminergic neural progenitor cell injection (XS411 Injection) received simultaneous approval for registration clinical trials in both China and the United States without any deficiencies requiring supplementation. This Phase 1/2 randomized, double-blind, controlled registration clinical trial, led by Director Jian Wang, Director Liang Chen, and Director Jing Zhang at Huashan Hospital, marks a historic first for the industry and represents a breakthrough 'high-standard' benchmark in the field."
Abogen Biosciences' ABO2102 IND Application Approved by Center for Drug Evaluation, NMPA
Recently, the Center for Drug Evaluation (CDE) under the National Medical Products Administration announced that ABO2102, a novel mRNA cancer vaccine targeting multiple KRAS mutations independently developed by Qiming Venture Partners portfolio company Abogen Biosciences, has received clinical trial implied approval for its Investigational New Drug (IND) application (acceptance number: CXSL2500388).
As China's first therapeutic cancer vaccine targeting multiple KRAS mutations, ABO2102 is applicable to solid tumor patients carrying any of five common KRAS mutations. It represents a major advancement in the challenging field of previously "undruggable" targets.
ABO2102 received FDA clinical trial approval in the United States in May this year. This approval in China marks a significant milestone of dual filing and dual approval in both China and the United States, fully demonstrating Abogen Biosciences' globally leading innovative capabilities and international strategic positioning in tumor immunotherapy.
Product Launches
Zhipu AI Launches GLM-4.5-Powered Zread to Reconstruct Technical Comprehension for Developers
Recently, Qiming Venture Partners portfolio company Zhipu AI launched Zread, powered by GLM-4.5. Zread is a large model-based developer productivity tool whose core features include deep learning of open-source projects, rapid onboarding to legacy codebases, and building team knowledge collaboration systems.
When developers input any GitHub repository, Zread generates guides containing architectural analysis, module explanations, and design patterns, while supporting multi-repository comparison, layered interpretation, and GitHub Trending project logic decomposition. Zread automatically organizes project structure and module dependencies to generate systematic documentation, helping developers get up to speed quickly — even when facing mountain-sized codebases as daunting as literary classics. Zread provides contributor maps, aggregated community comments, interactive annotations and Q&A, and supports uploading private projects to build internal team knowledge bases and technical documentation systems.
NorthMedi iFlowX™ Digital Pressure Pump Receives Regulatory Approval
Recently, the iFlowX™ Digital Pressure Pump developed by Qiming Venture Partners portfolio company NorthMedi officially received Class II medical device registration approval from the Guangdong Provincial Medical Products Administration. As the first digital pressure pump system with intelligent features, it leverages three key technologies to enhance surgical convenience and precision, advancing basic consumables into a new era of "digitalization and intelligence."
The product uses advanced algorithms to accurately identify calcification fracture characteristics and immediately triggers a flashing alarm, effectively ensuring surgical safety and improving patient prognosis. After detecting stable pressure values, it automatically starts timing to provide surgeons with precise drug-coated balloon inflation time references, enhancing surgical precision and standardization. It stores and clearly displays the peak pressure values and corresponding inflation durations for the last three inflation cycles, allowing physicians to quickly review historical inflation data.
Sino Biological Launches Chikungunya Virus Mutant Strain Recombinant Proteins and Related Antibodies
Recently, an imported Chikungunya fever outbreak occurred in Foshan, Guangdong Province. Qiming Venture Partners portfolio company Sino Biological (301047.SZ) responded swiftly by launching recombinant proteins and related antibodies for Chikungunya virus (CHIKV) mutant strains, having previously successfully developed CHIKV E1 and E2 recombinant proteins and related antibodies.
Sino Biological is committed to comprehensively supporting research institutions in Chikungunya virus mechanism research, as well as supporting vaccine development, antiviral drug development, and diagnostic reagent development by relevant enterprises.
Berry Genomics Officially Launches Localized Third-Generation HiFi Sequencing Thalassemia Detection Solution
Recently, Qiming Venture Partners portfolio company Berry Genomics (000710.SZ) introduced third-generation HiFi sequencing technology to deeply cultivate the thalassemia prevention and control field, officially launching a localized third-generation HiFi sequencing thalassemia detection solution that brings precision testing within reach.
Based on the Sequel II CNDx sequencing platform, the solution requires no DNA fragmentation and can directly read full-length gene sequences, accurately detecting genetic variation information and arrangement patterns from individual DNA molecules. It enables simultaneous testing for α-thalassemia and β-thalassemia from just 1 µL of whole blood.
Tech Strength
Multiple Qiming Venture Partners Portfolio Companies Appear at World Artificial Intelligence Conference 2025
The World Artificial Intelligence Conference 2025 (WAIC) was recently held in Shanghai. As one of the most influential industry events in global artificial intelligence, the conference adopted the theme "Intelligent Age: Shared Global Responsibility," continuing to serve as a "technology weathervane, application showcase, industry accelerator, and governance forum." It featured five core components: conference forums, exhibitions, awards competitions, intelligent experiences, and innovation incubation, comprehensively presenting the frontiers of AI technology, industrial trends, and latest practices in global governance. During the conference, major announcements included the 2025 AI Figures of the Year, the SAIL Award — WAIC's highest honor — the "Treasure of the Pavilion" selections, and other series awards.
As one of China's earliest and most extensively positioned investors in AI, Qiming Venture Partners hosted a forum at WAIC for the third consecutive year. This year's Qiming Venture Partners · Entrepreneurship and Investment Forum — "Venture Investment Enters the Resonance Cycle of AI Technology and Application" — was a sub-forum showcasing and exploring the latest breakthroughs in AI technology and application from an innovation perspective. Qiming Venture Partners hoped that by hosting this distinctive sub-forum, it could connect the themes of innovation, entrepreneurship, and venture capital, bringing good and useful information to the industry and the broader AI ecosystem through the sincere sharing of invited distinguished guests. From AI 1.0 to AI 2.0, Qiming Venture Partners has cumulatively invested in over 100 AI projects, with portfolio companies covering the full AI industry chain, helping multiple benchmark enterprises rise to prominence. It stands as one of the most active and influential investment institutions in artificial intelligence in China and across Asia.
Additionally, at WAIC 2025, Qiming Venture Partners portfolio companies including Infinigence AI, Transwarp Technology (688031.SH), Zhipu AI, Infinite Light Years, StepFun, Shengshu Technology, Galaxy Universal, Tashi Zhihang, Free Dimension, Unisound (09678.HK), Frontis, Houmo AI, Axera, CIX Technology, Mech-Mind Robotics, Zhichang Group, Future Intelligent, Tiamat Technology, Jialiang Medical, Temedica, Zuoyi Technology, and Insilico Medicine made appearances, demonstrating their technological innovation capabilities and growth potential through forums, core technology product showcases, and cutting-edge perspectives. Notably, Infinigence AI, Free Dimension, Temedica, Tiamat Technology, and Zuoyi Technology appeared in the Future Tech "Innovation Incubation Showcase Zone," co-established by WAIC and investment institutions including Qiming Venture Partners.
Zhipu AI CEO Zhang Peng, StepFun founder and CEO Daxin Jiang, and Infinigence AI co-founder and CEO Lixue Xia were named 2025 AI Figures of the Year. Xiaomi (01810.HK), Tiamat Technology, Biren Technology, and Galaxy Universal were listed among the SAIL Award TOP30 for Excellence in AI Leadership. Galaxy Universal, StepFun, Infinigence AI, Transwarp Technology, Infinite Light Years, Zhipu AI, and Tiamat Technology were selected for the WAIC "Treasure of the Pavilion" and series awards.
02/
WeRide Launches 7×24 Hour Stress Testing in Beijing
Recently, Qiming Venture Partners portfolio company WeRide (NASDAQ: WRD) announced that it has been approved to conduct public road testing of autonomous ride-hailing vehicles during nighttime hours (10 PM to 7 AM) in Beijing's High-Level Autonomous Driving Demonstration Zone. WeRide is among the first autonomous driving companies permitted to conduct nighttime road testing in Beijing, marking a critical step toward building a "7×24 hour" autonomous driving service network in the city and laying a solid foundation for truly all-weather, all-day autonomous mobility services.
The launch of this autonomous driving testing not only validates WeRide's technical system and safety mechanisms but also helps fill the public transportation gap during late night and early morning "service vacuum" periods, addressing dispatch challenges for冷门时段、偏远区域上车点 —冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门时段、偏远区域上车点冷门
Yunji Technology has always started from real demand, enabling robots in spaces like hotels to understand, deconstruct, and anticipate customer needs — constantly pushing boundaries in demand density, response elasticity, and service quality. What was once mechanical, reactive service has been upgraded to comprehensive, chain-style predictive service.
06/
Mofan Power Co-Develops China's First Megawatt-Class Fully Domestic Hydrogen Gas Turbine, Successfully Passes Acceptance
Recently, Qiming Venture Partners portfolio company Mofan Power announced that Zhejiang Energy Group and related units convened an acceptance review meeting in Hangzhou, Zhejiang Province for the "Megawatt-Class Small Natural Gas/Hydrogen Mixed-Fuel Gas Turbine R&D" project. Multiple experts in the gas turbine industry jointly reviewed and approved the project's R&D achievements, unanimously concluding that the project has reached internationally advanced standards. This not only means that Mofan Power's megawatt-class hydrogen-mixed gas turbine, forged through five years of refinement, was successfully tested at Zhejiang Energy Xiaoshan Power Plant's test base, but also represents a milestone in the company's journey toward developing domestically produced gas turbines for the broader hydrogen economy.
For wide-range hydrogen combustion, this project adopted the world's first micro-cluster combustion technology route. When numerous evaluation indicators — including operating windows, staged switching, emissions performance, wall temperature control, temperature distribution, and thermoacoustic characteristics — as well as practical boundary conditions such as nozzle configuration, channel structure, end matching, and even fuel orifice diameter were all laid before the team, hydrogen combustion proved to be a world-class challenge. Throughout this process, the combustion team made repeated trips between design and test iterations, conducting multiple rounds of small-scale experiments and full-temperature, full-pressure, full-scale tests, ultimately conquering the global challenge of "safe, stable, low-emission" combustion for both pure hydrogen and hydrogen-blended fuels. They completed the finalization of China's first megawatt-class fully domestic gas turbine hydrogen combustor.
07/
HyperStrong Product Successfully Passes China's Electrical Energy Storage System Lithium Battery and Battery Pack Safety Requirements Certification
Recently, Qiming Venture Partners portfolio company HyperStrong (688411.SH) saw its core product, the 314Ah-1P416S battery pack system, successfully pass certification under the People's Republic of China national standard GB 44240-2024 "Safety Requirements for Lithium Batteries and Battery Packs Used in Electrical Energy Storage Systems." The company received a compliance certification report issued by the National Energy Storage and Power Battery Quality Inspection and Testing Center, becoming one of the first companies in the industry to "pass" this standard.
According to the rigorous testing under GB 44240-2024, HyperStrong's self-developed 314Ah-1P416S battery pack system demonstrated exceptional performance across key dimensions including critical component durability, extreme environment stability, thermal abuse safety, and hardware-software response immediacy.
08/
Wecare Probiotics Brings Latest R&D Results and Product Solutions to Third Food Scientists Forum
Recently, Qiming Venture Partners portfolio company Wecare Probiotics participated in the Third Food Scientists Forum, bringing mainland China's first infant-grade listed strain BLa80 along with other latest R&D achievements and high-activity strain product solutions based on clinical evidence. The company engaged in deep exchanges with multiple academicians, scientists, experts, scholars, and industry elites from the food sector, jointly promoting deep integration of industry-academia-research and sustainable development of food science and technology.
At the conference, Wecare Probiotics made a stunning appearance with two major presentations: "The R&D Journey of BLa80, Mainland China's First Infant Probiotic Strain" and "The Innovation Journey of 100-Billion-CFU Bifidobacterium Yogurt." With hardcore technology breaking industry boundaries, the company unlocked new pathways to health through deep "industry-academia-research" integration. Meanwhile, its 100-billion-CFU bifidobacterium yogurt solution, with its outstanding high-activity empowerment and clinical efficacy performance, won the conference's Technology Innovation Award.
09/
Cornerstone Robotics Completes World's First Autonomous Surgery Validation in Clinical Scenario
Recently, Qiming Venture Partners portfolio company Cornerstone Robotics collaborated closely with a The Chinese University of Hong Kong research team to develop the world's first multi-functional automated embodied intelligence platform for surgical robots, and successfully completed the world's first autonomous surgery validation in a clinical scenario on Cornerstone Robotics' self-developed Sentire® laparoscopic surgical robot.
This breakthrough research was published in the top-tier authoritative robotics journal Science Robotics (impact factor: 27.5; 5-year impact factor: 32.9) under the title "Surgical Embodied Intelligence for General Task Automation in Laparoscopic Robot-Assisted Surgery." This marks the first time a Chinese laparoscopic surgical robot has completed live animal experiments in the embodied intelligence field, validating multi-task autonomous operation and human-robot collaboration capabilities. It represents a critical step forward in verifying the generality and practicality of China's surgical robot autonomy technology, demonstrating Chinese companies' technical breakthroughs and vertical integration strength in embodied intelligent surgical robots, and accelerating the industry's evolution toward greater intelligence, collaboration, and accessibility.
10/
AnteX Micro-Precision Surgical Robot Kai Assists in Completion of Scalp Scar Tissue Vascular Anastomosis Surgery
Recently, Shanghai Jiao Tong University School of Medicine Affiliated Ninth People's Hospital successfully performed a microsurgical robot-assisted surgery. Focusing on a complex keloid scar hyperplasia region of the scalp, the procedure relied on Qiming Venture Partners portfolio company AnteX Micro-Precision's microsurgical robot Kai to successfully complete the delicate anastomosis of the superficial temporal artery and posterior auricular vein, marking further clinical validation of domestic microsurgical robots' adaptability and precision in complex site repair.
The success of this surgery not only further expands the microsurgical robot Kai's adaptability in complex small spaces and sensitive regions, but also validates its high fault tolerance and stable output when handling non-standard vascular morphology and physiological trajectories. Building on conventional applications, the microsurgical robot Kai is gradually moving toward more customized clinical scenarios, continuously unleashing platform potential in specialized fields such as complex vascular reconstruction and craniofacial repair.
11/ SuperView Technology Debuts Full-Matrix Super-Resolution Imaging Products at 21st Biophysical Congress
At the 21st Biophysical Congress, Qiming Venture Partners portfolio company SuperView Technology showcased its Cell Xtreme live-cell full-time panoramic super-resolution microscope, Cell Xpanse live-cell wide-field full-time super-resolution microscope, and HIS-SIM ultra-sensitive super-resolution microscope.
Its annual flagship new product, the Cell Xtreme live-cell full-time panoramic super-resolution microscope, leverages key R&D upgrades including a new-generation multi-functional laser illumination lifting module, programmable high-order scanning imaging mode, label-free high-speed precision reconstruction algorithm deployment, and high-speed multi-channel AI segmentation model deployment. This provides a new system-level solution for long-duration, multi-modal super-resolution imaging of live cells, significantly broadening the observational boundaries of life science research.
Corporate Honors
01/
Three Qiming Venture Partners Portfolio Companies Named to China's Most Investment-Worthy and Most Growth-Potential Robot Company Rankings
During World Robot Conference 2025, the China Most Investment-Worthy Robot Companies TOP20 and China Most Growth-Potential Robot Companies TOP30 awards were announced at the robot venture capital themed exchange event. The former focuses on growth-stage enterprises, evaluating comprehensive indicators including commercialization progress, product maturity, and global technological leadership or influence; the latter emphasizes startup and early-stage companies, with particular attention to technological disruptiveness, CEO and team capabilities, and market business competitiveness.
Qiming Venture Partners portfolio company Galaxy Universal made the China Most Investment-Worthy Robot Companies TOP20 list, while Tashi Zhihang and Yuanling Intelligence earned spots on the China Most Growth-Potential Robot Companies TOP30 list.
02/
Xinsu Technology Named to China Synthetic Bio-Manufacturing TOP101
At the China Synthetic Biology Expo, the 2025 China Synthetic Bio-Manufacturing TOP101 list was officially released. Qiming Venture Partners portfolio company Xinsu Technology earned its place on the strength of its sustained breakthroughs in synthetic biology and proven industrialization capabilities.
The list was jointly launched by Synbio DeepWave and the China Synthetic Biology Expo, evaluating companies across market capitalization, sales revenue, fundraising history, technical capabilities, and systems architecture — painting a comprehensive picture of China's synthetic bio-manufacturing landscape. The "100" in TOP101 represents established leaders in industrial scale and technical moats; the "1" signifies the underlying technology disruptors poised to define next-generation bio-manufacturing.
PAST HIGHLIGHTS
Qiming Weekly | Qiming Venture Partners Portfolio Funding & Updates Vol. 28, 2025 Qiming Stars | Multiple Qiming Venture Partners Portfolio Companies at 2025 World Artificial Intelligence Conference
Founded in 2006, Qiming Venture Partners currently manages 11 USD funds and 7 RMB funds, with total assets under management reaching $9.5 billion. Since inception, the firm has focused on early- and growth-stage investments in Technology and Healthcare.
To date, Qiming Venture Partners has backed more than 580 high-growth innovative companies. Over 210 of these have gone public on the New York Stock Exchange, NASDAQ, Hong Kong Exchanges and Clearing Limited, Shanghai Stock Exchange, and Shenzhen Stock Exchange, or exited through M&A. More than 80 have become recognized unicorns or super-unicorns.
Many Qiming Venture Partners portfolio companies have grown into the most influential players in their respective fields, including Xiaomi (01810.HK), Meituan (03690.HK), Bilibili (NASDAQ:BILI, 09626.HK), Zhihu (NYSE:ZH, 02390.HK), Roborock (688169.SH), UBTECH (09880.HK), WeRide (NASDAQ:WRD), Insta360 (688775.SH), Gan & Lee Pharmaceuticals (603087.SH), Tigermed (300347.SZ, 03347.HK), Zai Lab (NASDAQ:ZLAB, 09688.HK), CanSino Biologics (688185.SH, 06185.HK), Schrödinger (NASDAQ:SDGR), MicroPort EP MedTech (688617.SH), Sanyou Medical (688085.SH), Amoy Diagnostics (300685.SZ), Berry Genomics (000710.SZ), Sinocelltech (688520.SH), Yuanxin Technology, Insilico Medicine, MediLink Therapeutics, LaNova Medicines, Zhipu AI, StepFun, and Biren Technology.